[{"NetIncomeLoss_1_Q3_USD":-56923.0,"StockIssuedDuringPeriodValueNewIssues_1_Q3_USD":25000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q3_USD":-442750000.0,"InterestIncomeOther_1_Q3_USD":2790.0,"CommitmentsAndContingencies_0_Q3_USD":null,"GeneralAndAdministrativeExpense_1_Q3_USD":59713.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"ProceedsFromRelatedPartyDebt_1_Q3_USD":112837.0,"Liabilities_0_Q3_USD":15540597.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":1139979.0,"PaymentsOfStockIssuanceCosts_1_Q3_USD":441969.0,"InterestAndDebtExpense_3_Q3_USD":100000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q3_USD":444255787.0,"ProceedsFromIssuanceOfPrivatePlacement_1_Q3_USD":10855000.0,"AssetsHeldInTrustNoncurrent_0_Q3_USD":442752790.0,"BusinessAcquisitionPercentageOfVotingInterestsAcquired_0_Q3_pure":0.5,"SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_0_Q3_shares":42367761.0,"FederalDepositInsuranceCorporationPremiumExpense_3_Q3_USD":250000.0,"CommonStockValue_0_Q3_USD":191.0,"IncomeTaxExpenseBenefit_1_Q3_USD":null,"BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_0_Q3_USD":24895463.0,"IncreaseDecreaseInAccruedLiabilities_1_Q3_USD":19347.0,"PaymentsToAcquireInvestments_1_Q3_USD":442750000.0,"PrepaidExpenseCurrent_0_Q3_USD":325442.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q3_USD":19347.0,"RepaymentsOfRelatedPartyDebt_1_Q3_USD":165081.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"OtherUnderwritingExpense_3_Q3_USD":544213.0,"AdditionalPaidInCapital_0_Q3_USD":5055629.0,"LiabilitiesCurrent_0_Q3_USD":44347.0,"NetCashProvidedByUsedInOperatingActivities_1_Q3_USD":-365808.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-56923.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q3_USD":1139979.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-56923.0,"StockholdersEquity_0_Q3_USD":5000004.0,"CashFDICInsuredAmount_0_Q3_USD":21995000.0,"PreferredStockSharesAuthorized_0_Q3_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":444218211.0,"PreferredStockValue_0_Q3_USD":null,"InvestmentIncomeInterest_1_Q3_USD":2790.0,"ProceedsFromIssuanceInitialPublicOffering_1_Q3_USD":433895000.0,"OperatingIncomeLoss_1_Q3_USD":-59713.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"StockRedeemedOrCalledDuringPeriodValue_1_Q3_USD":423677610.0,"Assets_0_Q3_USD":444218211.0,"AssetsHeldInTrust_0_Q3_USD":442752790.0,"ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_3_Q3_USD":8855000.0,"AssetsCurrent_0_Q3_USD":1465421.0,"IncreaseDecreaseInPrepaidExpense_1_Q3_USD":325442.0,"Ticker":"SMFR","CIK":"1818331","name":"CM LIFE SCIENCES, INC.","OfficialName":"Sema4 Holdings Corp. Class A Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"612399453.0","Country":"United States","Sector":"Technology","Industry":"Retail: Computer Software & Peripheral Equipment","Market":"NASDAQ","SP500":"nan","filed":"20201116"}]